Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KIRA-7 is an imidazopyrazine compound. KIRA-7 has an anti-fibrotic effect. KIRA-7 binds the IRE1α kinase (IC50: 110 nM) to allosterically inhibit its RNase activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,370.00 | |
50 mg | 6-8 weeks | $ 1,780.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | KIRA-7 is an imidazopyrazine compound. KIRA-7 has an anti-fibrotic effect. KIRA-7 binds the IRE1α kinase (IC50: 110 nM) to allosterically inhibit its RNase activity. |
Targets&IC50 | IRE1α kinase:110 nM |
In vitro | In the alveolar epithelial cell line MLE12, KIRA-7 inhibits XBP1 splicing [1]. |
In vivo | After Bleomycin exposure, mRNA levels of BiP and CHOP are significantly elevated, and treatment of Bleomycin-exposed mice with KIRA-7 decreased these levels. KIRA-7 (5 mg/kg; intraperitoneal injection; daily for 14 days; C57BL6 mice) treatment causes decreased spliced XBP1 and ATF4, compared to bleomycin exposed mice treated with vehicle. mRNA levels of collagen 1A1 and fibronectin are both significantly decreased by KIRA-7 treatment [1]. |
Molecular Weight | 466.51 |
Formula | C27H23FN6O |
CAS No. | 1937235-76-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KIRA-7 1937235-76-1 Others KIRA 7 KIRA7 inhibitor inhibit